Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose QP-6211 for postoperative pain after unilateral open hallux valgus surgery (Phase III)
CTR20251669Phase 3Completed
- Sponsor
- ClearPoint Biotech
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QP-6211 in postoperative pain, sponsored by ClearPoint Biotech. Started May 2025; status: completed.
02
Drugs
QP-6211
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20251669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251669.